Backer E T, Holtzer J D
Klinisch Chemisch Laboratorium, Diaconessenhuis, Leiden.
Ned Tijdschr Geneeskd. 1990 Sep 1;134(35):1705-7.
A man aged 68 years with choledocholithiasis and cholangitis, with no clinical signs suggestive of acute pancreatitis and with a low excretion of amylase in the urine, showed persistent hyperamylasaemia which appeared to be caused by macroamylasaemia. The macroamylase (an IgA-lambda-amylase complex) accounted for nearly all (90%) of the amylase activity in the serum. The activity of pancreatic amylase in serum, determined by an immunoinhibition test which selectively blocks salivary amylase activity, constituted 99% of the amylase activity in serum (normal reference range 19-71). We showed, however, that complexed salivary amylase is not inhibited in the test, resulting in a falsely-increased activity of pancreatic amylase in serum. We conclude that macroamylasaemia can lead to a clinically misleading increase in the activity of pancreatic amylase in serum.
一名68岁男性,患有胆总管结石和胆管炎,无急性胰腺炎的临床体征,尿淀粉酶排泄量低,但血清淀粉酶持续升高,似乎是由巨淀粉酶血症引起的。巨淀粉酶(一种IgA-λ-淀粉酶复合物)几乎占血清中淀粉酶活性的全部(90%)。通过选择性阻断唾液淀粉酶活性的免疫抑制试验测定,血清中胰腺淀粉酶的活性占血清淀粉酶活性的99%(正常参考范围19 - 71)。然而,我们发现试验中复合唾液淀粉酶未被抑制,导致血清中胰腺淀粉酶活性假性升高。我们得出结论,巨淀粉酶血症可导致血清中胰腺淀粉酶活性出现临床上具有误导性的升高。